CRL News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CR

Mkt Cap

$14.42B

Volume

532.82K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraThe global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.GlobeNewswire Inc. · Oct 12, 2026

PGNY or CRL: Which Is the Better Value Stock Right Now?A comparison of two Medical Services stocks reveals that Progyny (PGNY) presents a more attractive value investment opportunity than Charles River Laboratories (CRL). PGNY has a Zacks Rank of #2 (Buy) versus CRL's #3 (Hold), along with superior valuation metrics including a lower forward P/E ratio (12.40 vs 26.89) and a better Value grade (B vs D).Zacks Investment Research · Oct 7, 2026

Charles River Gains 75.8% in a Year: What's Driving the Rally?Charles River Laboratories (CRL) has outperformed the market with a 75.8% share price increase over the past year, driven by strong Research Models and Services (RMS) prospects and adoption of new approach methodologies. However, the company faces headwinds from uneven demand recovery across client segments, with small and midsized biotech revenues flat and currency fluctuations impacting reported growth. The company maintains a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 7, 2026

Global Animal Model Market Report 2026-2034 by Animal Type, Technology, Application, End User, and Region | CRISPR and Drug Discovery Drive Growth to USD 3.31 BillionThe global animal model market is projected to grow from USD 2.02 billion in 2025 to USD 3.31 billion by 2034, expanding at a CAGR of 5.46%. Growth is driven by rising pharmaceutical research, CRISPR-Cas9 advances, personalized medicine demand, and vaccine R&D expansion. Rodents remain the dominant animal type, while key players include Charles River Laboratories, Eurofins Scientific, and The Jackson Laboratory.GlobeNewswire Inc. · Oct 6, 2026

Is It Prudent to Add Teleflex Stock to Your Portfolio Now?Teleflex (TFX) reported Q2 2026 Vascular revenue growth of 9% driven by central access and hemostatic product demand, with Asia revenues jumping 59.5%. However, tariffs and acquisition costs pressured margins, with adjusted operating margin declining 520 basis points. The company improved its balance sheet with pro forma net leverage at 1.9X after debt repayment.Zacks Investment Research · Oct 6, 2026

Cell and Gene Therapy Biomanufacturing Market - Size, Share, and Forecast, 2026-2031 | Automation, Viral Vectors, and CDMO Expansion Drive 11.7% CAGR to $8.7 BillionThe global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.GlobeNewswire Inc. · Oct 5, 2026

Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?Aveanna Healthcare (AVAH) has significantly outperformed the Medical sector year-to-date, returning 56.4% compared to the sector's 2.8% average return. The company holds a Zacks Rank #2 (Buy) with consensus earnings estimates up 23.2% in the past quarter, indicating improved analyst sentiment. Charles River Laboratories (CRL) is another Medical stock outperforming with a 48.4% year-to-date return.Zacks Investment Research · Sep 30, 2026

Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Billion Market by 2030 as Tariffs and 8.9% Isolation Growth Reshape Competition Across Eurofins, WuXi AppTec, Cambrex and Charles RiverThe global pharmaceutical impurity synthesis and isolation services market is projected to grow from $1.3 billion in 2024 to $2.1 billion by 2030 at a 7.7% CAGR. Growth is driven by stricter regulatory requirements, increasing drug complexity, biologics expansion, and rising pharmaceutical outsourcing. Isolation services are expected to grow fastest at 8.9% CAGR, while analytical services will advance at 5.7% CAGR.GlobeNewswire Inc. · Sep 29, 2026

Rare Disease Contract Research Organization (CRO) Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share OutlookThe global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.GlobeNewswire Inc. · Sep 21, 2026

PGNY vs. CRL: Which Stock Is the Better Value Option?A comparison of two Medical Services sector stocks, Progyny (PGNY) and Charles River Laboratories (CRL), both with Zacks Rank #2 (Buy). Based on valuation metrics including forward P/E ratio (12.92 vs 24.87), PEG ratio (1.12 vs 2.76), and Value grades (B vs D), Progyny is identified as the superior value opportunity.Zacks Investment Research · Sep 18, 2026

CR

CRLCharles River Laboratories International, Inc.

CRL

Pay with—

Available Balance0.00

Your PositionYou don't own any CRL yet.

Related Tickers

Earnings